In HeLa cells, eRF3a degradation amplified aminoglycoside-induced readthrough at MECP2 nonsense mutations but did not trigger ...

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with ...

Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of ...

A laboratory proof of concept shows that engineered plants can release a noncanonical amino acid that activates selected ...

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary ...

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the appointment of Geno Germano to ...

For those who want to organize formats like FASTQ, SAM, and GO, as well as calculations in life sciences and information ...

Today, my husband brought me something and said, "It's not a paper about cats, but it's an interesting one." It's about how ...